Evogene and Pure Capital Agree to Reconstitute Board to Resolve Governance Dispute

Key Facts

1Evogene entered into a comprehensive cooperation agreement with Pure Capital Group to resolve existing differences.

2The agreement includes a reconstitution of the company's board of directors to end the shareholder dispute.

Evogene entered into a comprehensive cooperation agreement with Pure Capital Group to resolve existing differences. PR Newswire reported that the agreement includes a reconstitution of the company's board of directors to end a shareholder dispute, with Pure Capital agreeing to formally withdraw its notice regarding a special tender offer and enter into a 60-day standstill period.

EVGN closed at $0.4038 on October 5, 2026, with the stock trading between a day low of $0.371 and a high of $0.406 during that session. The settlement aims to align company leadership with shareholder interests and focus on its computational chemistry business following what the company described as constructive negotiations.